SAN DIEGO and TORONTO, April 24, 2018 -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, and Gregory K. Chow, Senior Vice President and Chief Financial Officer, will participate at the Bloom Burton & Co. Healthcare Conference on Wednesday, May 2, 2018 at 1:30 p.m. EDT:
| Time: | 1:30 p.m. EDT | |
| Date: | Wednesday, May 2, 2018 | |
| Location: | Sheraton Centre Toronto Hotel, Toronto, Canada | |
| Live webcast: | http://wsw.com/webcast/bloomburton3/apto |
The audio webcast can also be accessed through the Aptose website at www.aptose.com and will be archived shortly after the live event and available for 90 days.
About Aptose Biosciences
Aptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology. Aptose is advancing new therapeutics focused on novel cellular targets on the leading edge of cancer. The company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. For further information, please visit www.aptose.com.
About the Conference
The Bloom Burton & Co. Healthcare Investor Conference brings together U.S., Canadian and international investors who are interested in the latest developments in the Canadian healthcare sector. Attendees will have an opportunity to obtain corporate updates from the premier Canadian publicly traded and private companies through presentations and private meetings.
About Bloom Burton & Co.:
Bloom Burton & Co. (Bloom Burton Securities Inc.) is a firm dedicated to accelerating returns in the healthcare sector for both investors and companies. Bloom Burton has an experienced team of medical, scientific, pharmaceutical, legal and capital markets professionals who perform a deep level of diligence, which combined with our creative entrepreneurial approach, assists our clients in achieving the right monetization events. Bloom Burton and its affiliates provide capital raising, M&A advisory, equity research, business strategy and scientific consulting, advisory on direct investing and company creation and incubation services. Bloom Burton Securities Inc. is a member of the Investment Industry Regulatory Organization of Canada (IIROC) and is also a member of the Canadian Investor Protection Fund (CIPF).
For further information, please contact:
Aptose Biosciences
Greg Chow, CFO
647-479-9828
Email: [email protected]
| SMP Communications Susan Pietropaolo 201-923-2049 [email protected] | LifeSci Advisors Michael Wood Managing Director 646-597-6983 [email protected] |


Bernstein Names IAG, Ryanair as Top European Airline Stocks Ahead of Earnings
SK Hynix’s $28B U.S. IPO Draws Strong Demand as AI Chip Boom Fuels Investor Interest
Samsung Chairman Lee Jae-yong Expected to Meet Nvidia CEO Jensen Huang on AI and Chip Partnership
Goldman AM Sees Strong Buyout Opportunities in Japan, South Korea and Australia
Nippon Paint Reportedly Offers Up to €7.5 Billion for Akzo Nobel Decorative Paints Business
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside
Apple Sues OpenAI, Former Employees Over Alleged Trade Secret Theft
DOJ Grand Jury Investigates UAW President Shawn Fain Ahead of Union Election
Telenor to Buy Controlling Stake in Bahnhof in $630 Million Broadband Deal
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal
Deutsche Bank Fined A$2 Million by ASIC Over OTC Derivatives Reporting Errors
Sino Biopharm Stock Rises After AstraZeneca Licensing Deal, GSK Partnership Expansion
BHP Faces Port Hedland Strike Threat as Iron Ore Export Risks Grow
SK Hynix Prices Record U.S. ADR Offering at $149 After $200 Billion Investor Demand
Zhipu AI Raises HK$31.37 Billion in Discounted Share Sale to Accelerate AI Growth
SK Hynix Soars 13% in Nasdaq Debut After Record $26.5 Billion IPO 



